PHENYLEPHRINE HYDROCHLORIDE INJECTION USP 1% Solution

Țară: Canada

Limbă: franceză

Sursă: Health Canada

Ingredient activ:

Chlorhydrate de phényléphrine

Disponibil de la:

OMEGA LABORATORIES LIMITED

Codul ATC:

C01CA06

INN (nume internaţional):

PHENYLEPHRINE

Dozare:

10MG

Forma farmaceutică:

Solution

Compoziție:

Chlorhydrate de phényléphrine 10MG

Calea de administrare:

Intramusculaire

Unități în pachet:

1 ML

Tip de prescriptie medicala:

Spécialité médicale

Zonă Terapeutică:

ALPHA-ADRENERGIC AGONISTS

Rezumat produs:

Numéro de groupe d'ingrédients actifs (GIA) :0100662004; AHFS:

Statutul autorizaţiei:

COMMERCIALISÉ

Data de autorizare:

2001-07-30

Caracteristicilor produsului

PHENYLEPHRINE
HYDROCHLORIDE
INJECTION USP 1%
10 mg / mL
VASOPRESSOR
S.C. / I.M. / I.V.
WARNING:
PHYSICIANS
SHOULD
COM PLETELY
FAMlLIARlZE
THEM­
SELVES WlTH THE COMPLETE CON­
TENTS
OF
THIS
LEAFLET
BEFORE
PRESCRIBING THIS DRUG.
DESCRIPTION
Phenylephrine
Hydrochloride
Injection
is a vasoconstrictor and pressor drug
chemically related to epinephrine and
ephedrine.
PHARMACOLOGY
When applied topically or infiltrated into
the
tissues,
phenylephrine
produces
vasoconstriction that lasts longer than
that of epinephrine and ephedrine. Its
action on the heart contrasts sharply
with that of epinephrine and ephedrine,
in
that
it
slows
the
heart
rate
and
increases the stroke output, inducing no
disturbance in the rhythm of the pulse.
In therapeutic doses, it produces little if
any stimulation of either the spinal cord
or cerebrum. A singular advantage of
this drug is the fact that repeated injec­
tions produce comparable effects.
INDICATIONS
For the maintenance of blood pressure
during spinal and inhalation anesthesia,
and also for overcoming peripheral vas­
cular
failure
in
shock
and
shock­like
states,
drug­induced
hypotension
or
hypersensitivity. Employed to overcome
paroxysmal
supraventricular
tachy­
cardia, to prolong spinal anesthesia and
as a vasoconstrictor in regional anes­
thesia.
PRECAUTIONS
May be contraindicated in patients with
hypertension or ventricular tachycardia
or in patients who are hypersensitive to
the drug.
Should be used with extreme caution in
elderly
patients
or
those
with
hyper­
thyroidism,
bradycardia,
partial
heart
block,
myocardial
disease
or
severe
arteriosclerosis.
Vasopressors may cause serious car­
diac
arrhythmias
during
halothane
anesthesia
and
therefore
should
be
used only with great caution or not at all.
Contains sodium metabisulfite, a sulfite
that may cause allergic­type reactions
including
anaphylactic
symptoms
and
life­threatening or less severe asthmatic
episodes in certain susceptible people.
The overall prevalence of sulfite sensi­
tivity
in
the
general
population
is
un